Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Shay Capital LLC reduced its stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 94.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,000 shares of the biopharmaceutical company's stock after selling 425,000 shares during the quarter. Shay Capital LLC owned 0.07% of Achieve Life Sciences worth $88,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in Achieve Life Sciences by 185.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 4,905 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Achieve Life Sciences by 7.2% during the fourth quarter. Wells Fargo & Company MN now owns 74,933 shares of the biopharmaceutical company's stock worth $264,000 after purchasing an additional 5,059 shares during the last quarter. LPL Financial LLC raised its stake in shares of Achieve Life Sciences by 2.9% during the fourth quarter. LPL Financial LLC now owns 196,833 shares of the biopharmaceutical company's stock valued at $693,000 after acquiring an additional 5,500 shares during the last quarter. Barclays PLC increased its stake in shares of Achieve Life Sciences by 12.2% in the fourth quarter. Barclays PLC now owns 53,473 shares of the biopharmaceutical company's stock valued at $189,000 after buying an additional 5,818 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Achieve Life Sciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 755,845 shares of the biopharmaceutical company's stock worth $2,661,000 after purchasing an additional 6,736 shares during the last quarter. Institutional investors own 33.52% of the company's stock.

Insiders Place Their Bets

In related news, CFO Mark K. Oki purchased 10,000 shares of Achieve Life Sciences stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at $28,900. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.00% of the company's stock.

Achieve Life Sciences Trading Down 4.5%

ACHV stock traded down $0.14 during midday trading on Thursday, hitting $3.00. The stock had a trading volume of 60,026 shares, compared to its average volume of 229,871. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The firm has a market cap of $104.06 million, a P/E ratio of -2.65 and a beta of 1.49. The business has a fifty day moving average price of $2.51 and a two-hundred day moving average price of $3.27. Achieve Life Sciences, Inc. has a 1-year low of $1.84 and a 1-year high of $5.59.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.37). On average, sell-side analysts predict that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.